|
|||||
|
|
Locked nucleic acids (LNA) and medical applications |
|
| Authors: | Henrik Ørum Andreas Wolter Lars Kongsbak |
| Institution: | 1. Santaris Pharma A/S., B?gealle 3, DK-2970, H?rsholm, Denmark 2. Proligo GmbH, Georg-Heyken-Str, 14, 21147, Hamburg, Germany 3. Exiqon A/S, Bygstubben 9, DK-2950, Denmark |
| Abstract: | Summary Locked Nucleic Acid (LNA) is a novel, third generation DNA analogue that has the potential to impact strongly on the future development of a diversity of nucleic acid based technologies. The present chapter reviews the known biochemical properties of LNA and exemplifies how these have been used to improve both DNA diagnostic technologies and antisense therapeutics. |
| Keywords: | affinity antisense biodistribution capture probes cellular uptake detection-by-hybridisation LNA primers Locked Nucleic Acids (LNA) multiplex PCR nuclease resistance RNaseH recruiment specificity toxicity |
| 本文献已被 SpringerLink 等数据库收录！ | |